Global Allogenic Stem Cell Therapy Market – Industry Trends and Forecast to 2030

 Allogenic Stem Cell Therapy Market Analysis and Size

Scientists may gain a better understanding of how diseases and disorders develop by watching stem cells develop into cells in bones, the cardiovascular system, nerve endings, and other organs and tissues. Stem cells can be grown into new tissue for transplantation and genetic engineering. Researchers continue to learn more about stem cells and their applications in regenerative medicine, which will drive market growth during the forecast period of 2023-2030.

Data Bridge Market Research analyses that the allogenic stem cell therapy market, which was USD 994.9 million in 2022, is expected to reach USD 2109.50 million by 2030, at a CAGR of 9.85% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Allogenic Stem Cell Therapy Market Scope and Segmentation

Market Definition

Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to promote the repair response of dysfunctional,diseased, or injured tissue. Stem cells can develop into various types of cells in the body. Pluripotent and multipotent stem cells are the two main types of stem cells. Pluripotent stem cells are replicating cells that develop from embryonic or fetal tissues. Pluripotent stem cells help the cells and tissues develop in three primary germ layers: mesoderm, ectoderm, and endoderm.

Global Allogenic Stem Cell Therapy Market Dynamics

Drivers

• Increasing funding for stem cell research projects

The need for newer and better therapies for auto-immune, neurobiological, and coronary heart disease treatment has increased cumulative research activities and funding for cell-based research. For instance, the University of Sydney was awarded $6.3 million in June 2021 for three projects addressing adult vision loss and cardiovascular events and improving decisions about access to stem cell interventions. In the same year, Stanford physician-researchers were awarded nearly $31 million by the California Institute for Regenerative Medicine to begin first-in-human trials of stem therapies for treating stroke, heart failure, and a type of brain and spinal cord tumor. These are certain factors that propel the growth of the market.

• Rising number of launches

Increased product launches by key market players are expected to drive the market during the forecast period. For instance, LifeCell, a healthcare service provider, introduced an advanced umbilical cord-stem cell collection kit in August 2017 that protects neonatal stem cells from environmental damage and temperature fluctuations.

Opportunities

• Potential of stem cells for drug discovery

The ability to continuously develop functioning adult tissues in culture using directed differentiation opens up new avenues for drug discovery. Before conducting in vivo trials, researchers can create distinct cell lines and then test novel medications on each cell type in vitro to identify potential interactions. This is critical in developing medicines for use in veterinary research because of the possibility of species-specific combinations. The goal is to having the cell lines available for research use that will reduce the need for research animals because in vitro effects on human tissue will provide insight not previously known before the animal testing phase. These all are the factors which are expected to boost the market growth.

Restraints/Challenges

• Limited awareness regarding treatment

The main factors impeding the growth of the global allogenic stem cell therapy market are a lack of awareness about treatment options and ethical concerns about embryonic stem cells. For instance, according to data published by the National Center for Biotechnology Information, the main factor is the population's fear of unknown therapies and lack of awareness about treatment options. Furthermore, the high cost of the therapies leads to lower adoption, resulting in lower demand for the product globally.

This allogenic stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the allogenic stem cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Allogenic Stem Cell Therapy Market

The COVID-19 pandemic had a negative impact on the global allogenic stem cell therapy market due to a decrease in stem cell therapy research and development. The COVID-19 pandemic has caused significant disruption in research, manufacturing, and clinical development, according to the National Center for Biotechnology Information. Clinical trial disruption will erode the quality of clinical evidence for CGTs further, making a reliable HTA on the treatment benefits and economic impacts of CGTs even more difficult.

Furthermore, the current situation of COVID-19 is driving the growth of the market, as research activities for COVID-19 treatment are proceeding. Stem cell therapy may also be a promising treatment option for COVID-19 in the future. For instance, Lineage Cell Therapeutics, received a USD 5 million grant from the California Institute for Regenerative Medicine (CIRM) on May 6, 2020, to support the use of VAC, Lineage's allogeneic dendritic cell therapy, in the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Recent developments

• In December 2021, Century Therapeutics, a biotechnology company, collaborated with Bristol Myers Squibb, a pharmaceutical company, and signed a licence agreement to develop and commercialise up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and T cell ("iT") programmes for hematologic malignancies and solid tumors.

Global Allogenic Stem Cell Therapy Market Scope

The allogenic stem cell therapy market is segmented on the basis of product type, cell source, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Adult Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells

 Cell Source

• Adipose Tissue-Derived Mesenchymal Stem Cells
• Bone Marrow-Derived Mesenchymal Stem Cells
• Cord Blood/Embryonic Stem Cells
• Others

 Applications

• Musculoskeletal Disorders
• Wounds
• Injuries
• Cardiovascular Diseases
• Surgeries
• Gastrointestinal Diseases
• Other

 End Users

• Therapeutic Companies
• Cell and Tissues Banks
• Tools and Reagent Companies
• Service Companies

Allogenic Stem Cell Therapy Market Regional Analysis/Insights

The allogenic stem cell therapy market is analysed and market size insights and trends are provided by country, product type, cell source, application and end users as referenced above.

The countries covered in the allogenic stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the allogenic stem cell therapy market due to the improved investment scenario, technological advancements, and high economic growth.

Asia-Pacific is expected to grow at the highest growth rate from 2023 to 2030, owing to the surge in the prevalence of target chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The allogenic stem cell therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for allogenic stem cell therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the allogenic stem cell therapy market. The data is available for historic period 2011-2021.

Competitive Landscape and Allogenic Stem Cell Therapy Market Share Analysis

The allogenic stem cell therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to allogenic stem cell therapy market.

Some of the major players operating in the allogenic stem cell therapy market are:

• • Athersys Inc. (U.S.)
• • Mesoblast Ltd (Australia)
• • Biorestorative Therapies Inc. (U.S.)
• • Pluristem Inc. (Israel)
• • Brainstorm Cell Limited. (U.S.)
• • ViaCyte Inc. (U.S.)
• • Gamida Cell (U.S.)
• • HOPE BIOSCIENCES (U.S.)
• • Cellular Biomedicine Group (U.S.)
• • Smith+Nephew (U.K.)
• • MEDIPOST (South Korea)
• • ANTEROGEN.CO, LTD. (South Korea)
• • NuVasive Inc. (U.S.)
• • RTI Surgical (U.S.)
• • AlloSource (U.S.)
• • JCR Pharmaceuticals Co. Ltd. (Japan)
• • Takeda Pharmaceutical Company Limited (Japan) 

SKU-56872